Skip to main
RMD
RMD logo

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 50%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

ResMed is positioned for substantial growth in the respiratory care market, supported by a projected revenue increase of over high single digits (HSD%) in FY26, driven by rising sleep apnea diagnoses and an ageing population. The company has also demonstrated its commitment to returning value to shareholders through consistent dividend increases and an aggressive share repurchase strategy, while simultaneously investing in digital health initiatives. Furthermore, ResMed achieved a notable 12% year-over-year revenue increase in masks and other products across the U.S., Canada, and LATAM, highlighting its robust performance in key markets.

Bears say

The analysis indicates that ResMed may face medium-term challenges due to the increasing adoption of GLP-1 drugs, which are anticipated to disrupt volumes of Positive Airway Pressure (PAP) devices. Despite the company outpacing market growth, there is concern that the uptake of GLP-1 therapies could negatively impact future sales of its masks and devices. This creates a cautious outlook for ResMed given the potential for slowed revenue growth driven by changing treatment paradigms in sleep apnea management.

ResMed (RMD) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 50% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Buy based on their latest research and market trends.

According to 10 analysts, ResMed (RMD) has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $295.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $295.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.